A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with CLL/SLL
and NHL who have failed or are intolerant to standard of care.